Varenicline | |
---|---|
Molecular structure via molpic based on CDK |
Conformer [] | |
---|---|
Physical properties [] | |
---|---|
Molecular mass | 211.26 g/mol [1] |
Decomposition | Hazardous decomposition products: Hazardous decomposition products formed under fire conditions. - Carbon oxides, nitrogen oxides (NOx) [1] |
Predicted LogP | 0.8 [1] |
Structural Identifiers [] | |
---|---|
Molecular formula | C13H13N3 [1] |
IUPAC name | 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene [1] |
SMILES | C1C2CNCC1C3=CC4=NC=CN=C4C=C23 [1] |
InChI | InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2 [1] |
InChIKey | JQSHBVHOMNKWFT-UHFFFAOYSA-N [1] |
Dosing [] | |
---|---|
Elimination half-life | 24 hours |
Varenicline
Varenicline (also known as Ncgc00247735-01, Ncgc00247735-02, Vareniclin, Varenicline?, CP 526555; Champix; Chantix, s6985, CS-0396, DB01273, SB17430 or Ncgc00247735-03)
Stereochemistry []
Varenicline is a
Legal status
- Canada: Varenicline is a prescription only substance.
- United Kingdom: Varenicline is a prescription only substance.
- United States: Varenicline is a prescription only substance.
- European Union: Varenicline is a prescription only substance.